Departure of Directors or Certain




2019 Annual Salaries and Stock Option Awards



On December 12, 2018, the Board of Directors
(the Board) of Corvus Pharmaceuticals, Inc. (Corvus or the Company), approved, on recommendation
of the Compensation Committee of the Board, increases to the annual base salaries and stock option awards for the Companys
Chief Executive Officer, Chief Financial Officer and Chief Business Officer. The stock option awards to each of the executive officers
will be granted effective as of the close of business on December 12, 2018 with an exercise price equal to the closing price of
the Companys common stock as reported on The Nasdaq Global Market on the date of grant. The awards will be made pursuant
to the Companys 2016 Equity Incentive Awar d Plan and will vest in equal monthly installments over 48 months, subject to
continued service as of each vesting date.



The following table sets forth the 2019 annual
base salary and number of shares underlying the stock option awards for each of the named executive officers and principal financial
officer:





Name and Principal Position


2019 Base Salary

($)


Stock Option Award


(shares)



Richard A. Miller, M.D.


$

300,000


250,000



Chief Executive Officer





Leiv Lea


$

350,000


100,000



Chief Financial Officer





Daniel W. Hunt, J.D.


$

386,250


50,000



Senior Vice President and Chief Business Officer







Departure of Director



On December 12, 2018, Peter Moldt Ph.D. notified the Company of
his intention to resign from the Board as well as each of the audit committee and nominating and corporate governance committee
in the first half of 2019. Dr. Moldts resignation is not due to any disagreement with the Company, the Board or management
of the Company.










SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.








CORVUS PHARMACEUTICALS, INC.







Date: December 14, 2018



By:


/s/ Leiv Lea






Leiv Lea






Chief Financial Officer

























makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback